FDA Briefing Document Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) November 5, 2013 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and D - Oncology Drug Advisory Committee - Document - PDFSEARCH.IO - Document Search Engine

Back to Results

First Page	Meta Content
	FDA Briefing Document Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) November 5, 2013 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and D Add to Reading List Open Document File Size: 120,73 KB Share Result on Facebook Company Merck / Bristol Myers Squibb Co. / Novartis Pharmaceuticals Corporation / FDA Briefing Document Page 4 Best Pharmaceuticals / Nivolumab COMPANY / / Event FDA Phase / / IndustryTerm biological products / treatment of unresectable or metastatic melanoma / products / therapies for pediatric rare diseases / biologic products / chemical and physical agents / treatment of pediatric cancer / / MedicalCondition tumor / rare diseases / pediatric cancer / cancer / tumors / disease / original rare disease / rhabdomyosarcoma and other tumor / rare disease / osteosarcoma / neuroblastoma / childhood cancer / rare pediatric disease / factors influencing tumor / sarcoma / melanoma / Therefore pediatric tumors / pediatric tumor / non-small cell lung cancer / adult cancers / pediatric cancers / selected pediatric tumor / cell carcinoma / pediatric rare disease / recurrent solid tumors / pediatric rare diseases / refractory malignant solid tumor / metastatic melanoma / rhabdomyosarcoma / / MedicalTreatment immunotherapies / chemotherapy / / Organization Congress / Oncology Subcommittee / office of Hematology and Oncology Products / Food and Drug Administration / Review Division / DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring / Oncologic Drugs Advisory Committee / FDA Briefing Document Pediatric Oncology Subcommittee / Advisory Committee / Pediatric Oncology Subcommittee / / Person Summaries Morning / Richard Pazdur / / Position Director / Executive / / Product Act / MK3475 / CA209070 / / ProvinceOrState Maryland / / Technology chemotherapy / drug development / / URL http / SocialTag Clinical pharmacology Food and Drug Administration Therapeutics United States Public Health Service Piperazines Biosimilar Ipilimumab Food and Drug Administration Amendments Act Moxifloxacin Pharmacology